Understanding Melanotan II Dosing in Research
Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (?-MSH) that has been extensively studied for its effects on melanogenesis, appetite regulation, and other melanocortin receptor-mediated processes. This guide covers the dosing protocols used across published research studies.
Mechanism of Action
Melanotan II is a non-selective melanocortin receptor agonist, binding to MC1R through MC5R with varying affinities. The MC1R activation drives melanogenesis (pigmentation), while MC4R activation influences appetite and energy homeostasis. This broad receptor binding profile accounts for the peptide’s diverse research applications and the importance of precise dosing.
Research Dosing Protocols
Published research on Melanotan II has utilized two primary dosing phases: a loading phase and a maintenance phase.
Loading Phase Protocol
Research studies typically employed an initial loading phase to establish baseline melanocortin receptor saturation:
- Starting dose: 0.25mg subcutaneous injection
- Escalation: Increase by 0.25mg increments as tolerated
- Target loading dose: 0.5-1.0mg daily
- Loading duration: Typically 2-3 weeks in research protocols
Maintenance Phase Protocol
After the loading phase, research protocols typically reduce to maintenance dosing:
- Frequency: 2-3 times per week
- Dose: 0.5-1.0mg per administration
- Duration: Variable based on research endpoints
Dose-Response Relationships
Research has demonstrated that melanogenesis response follows a dose-dependent curve with individual variation based on baseline melanocortin receptor density and skin phototype. Subjects with lighter baseline pigmentation (Fitzpatrick Types I-II) typically required longer loading periods compared to those with darker baseline pigmentation.
Reconstitution Guidelines
MT-II is supplied as a lyophilized powder and requires reconstitution with bacteriostatic water. A standard approach uses 1-2mL of bacteriostatic water per vial. See our complete reconstitution guide for step-by-step instructions and concentration calculations.
Administration & Timing
Research protocols administered MT-II via subcutaneous injection, typically in the abdominal region. Studies noted that administering the peptide in the evening or before bed helped manage the transient nausea that can occur in the first few administrations. This side effect typically diminished with continued use in research subjects.
Storage Requirements
Lyophilized MT-II should be stored at -20°C for long-term stability. Reconstituted solution should be refrigerated at 2-8°C. Protect from light exposure as the peptide is photosensitive. Review our storage guide for complete peptide handling protocols.
Safety Profile in Research
Common observations in MT-II research include transient nausea (especially during initial dosing), facial flushing, and fatigue. These effects were typically mild and self-limiting. The non-selective nature of MT-II’s receptor binding means researchers should be aware of effects across multiple melanocortin pathways.
This material is for research and educational purposes only. Melanotan II is sold for research use only. Visit our COA page for third-party purity verification.